BridgeBio Pharma Inc

NASDAQ:BBIO  
7.62
+0.22 (+3.04%)
Debt Financing / Related, Divestitures / Spin-offs

BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher For $110 Million

Published: 05/13/2022 11:45 GMT
BridgeBio Pharma Inc (BBIO) - Bridgebio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million and Defers Principal Payment on Senior Debt by Two Years.
Bridgebio - Retains Access to Up to $100 Million in Delayed Debt Draws Through Year End 2022, Subject to Certain Conditions.